Coming Soon
Find comprehensive information on Amphetamine Use Disorder (Stimulant Use Disorder, Methamphetamine Use Disorder) diagnosis, including clinical documentation, medical coding, and healthcare resources. Learn about diagnostic criteria, treatment options, and best practices for accurate record-keeping related to amphetamine and stimulant addiction. This resource is designed for healthcare professionals seeking guidance on proper coding and documentation for Amphetamine Use Disorder.
Also known as
Stimulant use disorder
Covers amphetamine and other stimulant related disorders.
Other stimulant use disorder
Includes other specified stimulant use disorders.
Cocaine use disorder
While not amphetamine, it's a related stimulant disorder.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the amphetamine use disorder mild, moderate, or severe?
When to use each related code
| Description |
|---|
| Problematic amphetamine use leading to impairment. |
| Problematic stimulant use, including cocaine, not just amphetamines. |
| Problematic methamphetamine use leading to impairment. |
Coding requires specifying the type of amphetamine (e.g., methamphetamine, dextroamphetamine) for accurate billing and data analysis. Unspecified type leads to data integrity issues.
Confusing substance use disorder with amphetamine-induced disorders (e.g., psychosis, anxiety) can lead to inaccurate coding and clinical documentation improvement (CDI) queries.
Lack of documentation specifying the severity (mild, moderate, severe) and course specifiers (in early remission, in sustained remission) impacts reimbursement and quality reporting.
Q: What are the most effective evidence-based interventions for stimulant use disorder, specifically methamphetamine and amphetamine, in a primary care setting?
A: Addressing stimulant use disorder, including methamphetamine and amphetamine misuse, in primary care requires a multi-faceted approach rooted in evidence-based interventions. Contingency management, utilizing motivational incentives, has demonstrated efficacy in promoting abstinence. Cognitive behavioral therapy (CBT) equips patients with coping mechanisms to manage cravings and triggers. Medication-assisted treatment (MAT), while limited for stimulants, can include bupropion for methamphetamine dependence to reduce cravings and withdrawal symptoms. Integrating these interventions with harm reduction strategies, such as safe injection practices and overdose education including naloxone distribution, is crucial. Explore how combining behavioral therapies like CBT with contingency management can improve patient outcomes in primary care. Consider implementing routine screening for stimulant use disorder using validated tools to facilitate early intervention.
Q: How can I differentiate between amphetamine-induced psychosis and primary psychotic disorders like schizophrenia when assessing a patient presenting with psychotic symptoms?
A: Differentiating between amphetamine-induced psychosis and primary psychotic disorders like schizophrenia requires careful clinical assessment. While overlapping symptoms exist, several key features can aid in the distinction. Amphetamine-induced psychosis often presents with prominent visual and tactile hallucinations, paranoia, and agitation, with symptoms typically resolving within days to weeks of stimulant cessation. In contrast, schizophrenia often involves a broader range of symptoms, including negative symptoms like flat affect and avolition, as well as a longer duration of illness with persistent or episodic symptoms even without stimulant use. A thorough history, including substance use patterns and family history of psychotic disorders, is essential. Consider implementing validated screening tools for substance use and psychosis. Learn more about the diagnostic criteria for primary psychotic disorders to enhance differential diagnosis and ensure appropriate treatment planning.
Patient presents with features consistent with Amphetamine Use Disorder (Stimulant Use Disorder, Methamphetamine Use Disorder). The patient reports a maladaptive pattern of amphetamine use leading to clinically significant impairment or distress, as manifested by meeting at least two of the following DSM-5 criteria within a 12-month period: amphetamine taken in larger amounts or over a longer period than intended; persistent desire or unsuccessful efforts to cut down or control amphetamine use; a great deal of time spent in activities necessary to obtain, use, or recover from the effects of amphetamine; craving, or a strong desire or urge to use amphetamine; recurrent amphetamine use resulting in a failure to fulfill major role obligations at work, school, or home; continued amphetamine use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of amphetamine; important social, occupational, or recreational activities are given up or reduced because of amphetamine use; recurrent amphetamine use in situations in which it is physically hazardous; amphetamine use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by amphetamine; tolerance, as defined by either a need for markedly increased amounts of amphetamine to achieve intoxication or desired effect or a markedly diminished effect with continued use of the same amount of amphetamine; withdrawal, as manifested by either the characteristic amphetamine withdrawal syndrome or amphetamine (or a closely related substance, like a stimulant) is taken to relieve or avoid withdrawal symptoms. Differential diagnoses considered include other substance use disorders, mood disorders, and anxiety disorders. Treatment plan includes psychosocial interventions such as cognitive behavioral therapy (CBT) and motivational interviewing, contingency management, and consideration for pharmacotherapy options. Patient education provided regarding addiction treatment, relapse prevention, and community resources. Follow-up appointment scheduled to monitor progress and adjust treatment plan as needed. ICD-10 code F15.10 for Amphetamine Use Disorder will be utilized for billing and coding purposes. Prognosis guarded given the chronic nature of addiction.